Eugammon of Cyrene

FLUORETH-LAD

Clinical data
Other names	TRALA-15; FE-LAD; 6-(2-Fluoroethyl)-6-nor-LSD; 6-(2-Fluoroethyl)-LAD; N,N-Diethyl-6-(2-fluoroethyl)-9,10-didehydroergoline-8β-carboxamide
Drug class	Serotonin receptor modulator[1]
Identifiers
IUPAC name (6aR,9R)-N,N-diethyl-7-(2-fluoroethyl)-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
CAS Number	2757566-18-8 Y
PubChem CID	168105608
Chemical and physical data
Formula	C21H26FN3O
Molar mass	355.457 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCN(CC)C(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)CCF
InChI InChI=1S/C21H26FN3O/c1-3-24(4-2)21(26)15-10-17-16-6-5-7-18-20(16)14(12-23-18)11-19(17)25(13-15)9-8-22/h5-7,10,12,15,19,23H,3-4,8-9,11,13H2,1-2H3/t15-,19-/m1/s1 Key:UYFDKYZWVLEHQH-DNVCBOLYSA-N

FLUORETH-LAD (TRALA-15), or FE-LAD, also known as 6-(2-fluoroethyl)-LAD or 6-(2-fluoroethyl)-6-nor-LSD, is a lysergamide derivative. It was first proposed by Alexander and Ann Shulgin in their book TiHKAL,^[2] but was never synthesised by Shulgin. Synthesis and activity data for the compound were first reported in a 2022 patent by Matthias Grill, in which pharmacological testing showed it to have similar affinity to LSD at some targets such as the 5-HT_1A and 5-HT_2A serotonin receptors, but much lower affinity at other targets such as 5-HT_2C and at dopamine receptors, giving it comparatively greater selectivity compared to LSD. Currently new lysergamide derivates are in the development phase at MiHKAL GmbH in Switzerland.^[1]

• CE-LAD
• AL-LAD
• ETH-LAD
• PRO-LAD

• FLUORETH-LAD (TRALA-15) - Isomer Design